Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8337937 | The Journal of Steroid Biochemistry and Molecular Biology | 2017 | 30 Pages |
Abstract
Daily 6.5 mg (0.50%) prasterone appears to be at least as efficacious as 0.3 mg CEE or 10 μg E2 for treatment of the VVA symptoms. In summary, the beneficial effects on the VVA symptomatology can be obtained by the addition of a small amount of intravaginal prasterone to compensate for the low serum concentration of prasterone observed in the majority of women after menopause without concerns about systemic effects.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry
Authors
David F. Archer, Fernand Labrie, Marlene Montesino, Céline Martel,